NASDAQ:ARQL - ArQule Stock Price, News & Analysis

$7.99
+0.03 (+0.38 %)
(As of 09/19/2019 12:47 PM ET)
Today's Range
$7.82
Now: $7.99
$8.04
50-Day Range
$7.80
MA: $9.04
$10.40
52-Week Range
$2.23
Now: $7.99
$12.22
Volume15,473 shs
Average Volume1.71 million shs
Market Capitalization$960.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARQL
CUSIP04269E10
Phone781-994-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.76 million
Book Value$0.72 per share

Profitability

Net Income$-15,480,000.00
Net Margins-349.34%

Miscellaneous

Employees36
Market Cap$960.88 million
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.


ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $1.43 million. ArQule had a negative return on equity of 33.45% and a negative net margin of 349.34%. During the same quarter last year, the business posted $0.05 earnings per share. View ArQule's Earnings History.

When is ArQule's next earnings date?

ArQule is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for ArQule.

What guidance has ArQule issued on next quarter's earnings?

ArQule updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of $-0.37--0.35 for the period, compared to the Thomson Reuters consensus estimate of $-0.38. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $4.25 million.

What price target have analysts set for ARQL?

6 brokerages have issued 12-month price targets for ArQule's stock. Their predictions range from $11.00 to $13.00. On average, they anticipate ArQule's share price to reach $12.3333 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View Analyst Price Targets for ArQule.

What is the consensus analysts' recommendation for ArQule?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.

What are Wall Street analysts saying about ArQule stock?

Here are some recent quotes from research analysts about ArQule stock:
  • 1. HC Wainwright analysts commented, "We are initiating coverage with a Buy rating and $13 price target. ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ 531 for B-cell malignancies and miransertib for rare tissue overgrowth diseases. Registrational trials for these two drugs are expected to begin in 2H19. We believe these trials will drive more interest in ArQule and push the stock higher. For the other two products, ARQ 751 and derazantinib, we consider them free call options. Management projects cash and marketable securities on the balance sheet will total approximately $160M at the end of 2019, which is forecast to fund operating expenses into 2022. Targeting treatment resistance in B-cell malignancies." (9/16/2019)
  • 2. According to Zacks Investment Research, "ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. " (7/29/2019)

Has ArQule been receiving favorable news coverage?

News headlines about ARQL stock have trended negative on Thursday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ArQule earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for ArQule.

Who are some of ArQule's key competitors?

What other stocks do shareholders of ArQule own?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:
  • Mr. Paolo Pucci, CEO & Director (Age 58)
  • Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
  • Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
  • Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
  • Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer

Who are ArQule's major shareholders?

ArQule's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.47%), Vanguard Group Inc. (4.69%), Eagle Asset Management Inc. (2.54%), Candriam Luxembourg S.C.A. (2.51%), Point72 Asset Management L.P. (2.26%) and Carillon Tower Advisers Inc. (2.19%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.

Which major investors are selling ArQule stock?

ARQL stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Sofinnova Investments Inc., Alps Advisors Inc., Handelsbanken Fonder AB, AQR Capital Management LLC, GSA Capital Partners LLP, Morgan Stanley and Moloney Securities Asset Management LLC. View Insider Buying and Selling for ArQule.

Which major investors are buying ArQule stock?

ARQL stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Point72 Asset Management L.P., Carillon Tower Advisers Inc., Emerald Advisers LLC, Marshall Wace North America L.P., Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A. and Nuveen Asset Management LLC. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.

How do I buy shares of ArQule?

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $7.98.

How big of a company is ArQule?

ArQule has a market capitalization of $959.67 million and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.View Additional Information About ArQule.

What is ArQule's official website?

The official website for ArQule is http://www.arqule.com/.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]


MarketBeat Community Rating for ArQule (NASDAQ ARQL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  668
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel